Last reviewed · How we verify
Clopixol (ZUCLOPENTHIXOL)
Clopixol works by blocking the 5-hydroxytryptamine receptor 6, which helps to regulate mood and reduce symptoms of schizophrenia.
Clopixol, also known as Zuclopenthixol, is a high-risk QT prolonging agent used to treat schizophrenia. It is a small molecule that targets the 5-hydroxytryptamine receptor 6. The commercial status of Clopixol is unclear, but it is likely patented. Key safety considerations include its potential to prolong the QT interval, which can increase the risk of serious cardiac arrhythmias. Clopixol is not FDA-approved, but it is approved for use in some countries to treat schizophrenia.
At a glance
| Generic name | ZUCLOPENTHIXOL |
|---|---|
| Drug class | High Risk QT Prolonging Agents |
| Target | 5-hydroxytryptamine receptor 6 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | discontinued |
Mechanism of action
Imagine your brain is like a city with many different streets and intersections. The 5-hydroxytryptamine receptor 6 is like a traffic light that helps control the flow of information between different parts of the brain. By blocking this receptor, Clopixol helps to reduce the 'traffic' of abnormal signals that can contribute to symptoms of schizophrenia.
Approved indications
- Schizophrenia
Common side effects
- Blood prolactin abnormal
- Anosognosia
- Disturbance in social behaviour
- Sexual dysfunction
- Metabolic disorder
- Personality change
- Dystonia
- Sedation
- Dyskinesia
- Suicide attempt
- Blood glucose increased
- Schizophrenia
Drug interactions
- High Risk QT Prolonging Agents
Key clinical trials
- Long-acting Injectable Antipsychotics for Mental Ill-Health in Pregnancy and Postpartum
- Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR. (PHASE4)
- Study Comparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Patients With Schizophrenia Spectrum Disorder: a Personalized Medicine Approach (PHASE2)
- Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients (PHASE4)
- Pharmacovigilance in Gerontopsychiatric Patients (PHASE3)
- Antipsychotics and Risk of Hyperglycemic Emergencies
- Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis (PHASE3)
- Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clopixol CI brief — competitive landscape report
- Clopixol updates RSS · CI watch RSS